Cumulative Burden of Myocardial Dysfunction in Cardiac Amyloidosis Assessed Using Four-Chamber Cardiac Strain

Yuichiro Kado, MD, Masaru Obokata, MD, PhD, Yasufumi Nagata, MD, PhD, Tomoko Ishizu, MD, PhD, Karima Addetia, MD, Kazutaka Aonuma, MD, PhD, Masahiko Kurabayashi, MD, PhD, Roberto M. Lang, MD, Masaaki Takeuchi, MD, PhD, and Yutaka Otsuji, MD, PhD, *Kitakyushu, Maebashi, and Tsukuba, Japan; and Chicago, Illinois*

Background: The aim of this study was to test the hypothesis that prognosis in patients with cardiac amyloidosis is closely coupled with amyloid burden in all four cardiac chambers. The goal was to evaluate longitudinal strain (LS) in each cardiac chamber and to determine whether LS in specific cardiac chambers is preferentially associated with prognosis over conventional two-dimensional echocardiographic parameters in patients with cardiac amyloidosis.

Methods: Patients with two phenotypes of left ventricular (LV) hypertrophy (cardiac amyloidosis in 55 patients and nonobstructive hypertrophic cardiomyopathy in 40 patients) and 55 healthy subjects were retrospectively enrolled for the simultaneous assessment of LS of all four cardiac chambers in the apical four-chamber view. Patients with cardiac amyloidosis were followed up to record major adverse cardiovascular events, including cardiac death, heart transplantation, nonfatal myocardial infarction, ventricular tachyarrhythmia, and exacerbation of heart failure requiring hospitalization.

Results: LS in each chamber was significantly depressed in patients with both LV hypertrophy phenotypes compared with healthy subjects. Right atrial LS was significantly lower in patients with cardiac amyloidosis than those with nonobstructive hypertrophic cardiomyopathy after adjusting for LV ejection fraction and LV mass index. During a median follow-up period of 10 months, major adverse cardiovascular events developed in 22 patients with cardiac amyloidosis. Four-chamber LS were significantly associated with major adverse cardiovascular events, with incremental value over traditional echocardiographic parameters.

Conclusions: Cardiac amyloidosis involves all cardiac chambers, and thus, chamber-specific strain analysis may be useful to assess the total cumulative burden of cardiac dysfunction. (J Am Soc Echocardiogr 2016; **I** : **I** - **I**.)

Keywords: Amyloidosis, Four-chamber, Speckle-tracking, Strain, Prognosis

Amyloidosis is characterized by extracellular deposition of amyloid fibrils in multiple systemic organs. Because cardiac amyloidosis is a major cause of death, several echocardiographic parameters have

0894-7317/\$36.00

Copyright 2016 by the American Society of Echocardiography. http://dx.doi.org/10.1016/j.echo.2016.07.017 been demonstrated to be significant predictors of poor prognosis. Although clinical outcome is generally related to the type of amyloidosis, the prognosis of each patient remains variable.¹⁻³ Therefore, the identification of patients at increased risk for cardiac events remains challenging.

Strain and strain rate are useful parameters for quantifying cardiac chamber mechanics, and their prognostic value has been demonstrated in several cardiovascular diseases.^{4,5} Previous studies have reported the utility of tissue Doppler or speckle-tracking analysis, revealing that impaired global left ventricular (LV) longitudinal strain (LS) and basal LS were more closely associated with worse clinical outcomes compared with conventional echocardiographic parameters in patients with cardiac amyloidosis.^{6,7} Myocardial infiltration in cardiac amyloidosis involves not only the left ventricle but also other cardiac chambers.⁸⁻¹¹ The severity and extent of cardiac involvement are associated with worse outcomes.¹² We hypothesized that prognosis in patients with cardiac amyloidosis is closely coupled to the amount of amyloid burden in all four cardiac chambers, and thus, assessment of LS in each chamber with two-dimensional (2D) speckle-tracking analysis has the potential to identify high-risk patients

From the Department of Cardiovascular Surgery (Y.K.), the Second Department of Internal Medicine (Y.K., Y.N., Y.O.), and the Department of Laboratory and Transfusion Medicine (M.T.), University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan; the Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Maebashi, Japan (M.O., M.K.); the Cardiovascular Division, University of Tsukuba, Tsukuba, Japan (T.I., K.A.); and the Noninvasive Cardiac Imaging Laboratory, University of Chicago Medical Center, Chicago, Illinois (K.A., R.M.L.).

Dr. Takeuchi received an equipment grant from Epsilon Imaging.

Reprint requests: Masaaki Takeuchi, MD, PhD, FASE, University of Occupational and Environmental Health, School of Medicine, Department of Laboratory and Transfusion Medicine, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, Japan (E-mail: takeuchi@med.uoeh-u.ac.jp).

2 Kado et al

ARTICLE IN PRESS

Ultrasound AS, Horten, Norwayl). The Digital Imaging and

Communications in Medicine-formatted files were then exported

to a personal computer, and data were analyzed using vendor-

independent 2D speckle-tracking software (EchoInsight; Epsilon

Imaging) by an experienced observer. For the simultaneous measure-

Abbreviations and Acronyms

AL = Amyloid light chain

ATTR = Transthyretin-related

HCM = Hypertrophic cardiomyopathy

IQR = Interquartile range

LA = Left atrial

LS = Longitudinal strain

LV = Left ventricular

LVH = Left ventricular hypertrophy

MACE = Major adverse cardiovascular event

RA = Right atrial

RV = Right ventricular

2D = Two-dimensional

pared with clinical and conventional echocardiographic parameters.

METHODS

Study Subjects

We retrospectively searched for patients with high probabilities of cardiac amyloidosis who were referred to the echocardiography laboratories of four university hospitals (the University of Occupational and Environmental Health, the University of Chicago, the University of Tsukuba, and Gunma University). The diagnosis of cardiac amyloidosis was confirmed either by demonstrating amyloid deposits on endomyocardial biopsy or, in patients with the typical echocardiographic features of cardiac amyloidosis (mean LV thickness \ge 12 mm),^{7,14-16} by demonstrating amyloid depositions on histologic examination of a biopsy from other tissues (e.g., abdominal fat pad, rectum). The type of amyloidosis was then assessed by immunohistochemistry. Among 106 patients screened, 51 patients were excluded because biopsy was not performed (n = 19), biopsy was performed but there was no amyloid deposition or histology could not determine the type of amyloidosis (n = 21), echocardiographic image quality was poor (n = 2), or no follow-up information was available (n = 9), leaving 55 patients in the final study group. We also enrolled 40 age- and gendermatched patients with nonobstructive HCM and 55 healthy subjects. Diagnosis of HCM was defined as the presence of increased LV wall thickening (\geq 15 mm) in the LV wall in the absence of any identifiable cause. Healthy subjects were selected from the database, which had been used in a previous publication.¹³ The study, for which the requirement to obtain written informed consent was waived, adhered to the Declaration of Helsinki and was approved by the human research and ethics committee of each hospital.

Echocardiography

All patients underwent standard echocardiographic evaluation following the guidelines of the American Society of Echocardiography using commercially available ultrasound systems (iE33 IPhilips Medical System, Andover, MAJ or Vivid 7 [GE Vingmed

for future cardiac events. Recently, a novel vendor-independent 2D speckle-tracking software package (Research; Epsilon Imaging, Ann Arbor, MI) has enabled simultaneous measurements of LS in all cardiac chambers with the use of the apical four-chamber view.¹³

The purposes of this study were (1) to compare chamberspecific LS in patients with cardiac amyloidosis and another phenotype of LV hypertrophy (LVH), hypertrophic cardiomyopathy (HCM), and control subjects; (2) to determine if simultaneous assessment of four-chamber LS is associated with cardiac events in patients with cardiac amyloidosis; and (3) to determine whether chamber-specific LS adds incrementally to risk stratification com-

ment of LS in all chambers throughout the same cardiac cycle, an apical four-chamber view was recorded. Care was taken to include all cardiac chambers in the data acquisition. The endocardial and epicardial borders of both the left and right ventricles were manually traced in the end-diastolic frame, and the region of interest adjusted to track all myocardial segments adequately. Subsequently, the software (EchoInsight for Research, Epsilon Imaging) divided the right ventricular (RV) and LV myocardium into six regions and performed speckle-tracking analysis, resulting in the generation of averaged LS curves of the LV and RV segments. For the calculation of left atrial (LA) and right atrial (RA) LS, the same software was used after tracing both the endocardial and epicardial borders of the atrial wall in the end-systolic frame (Supplemental Figure 1). The peak LS of each chamber was obtained from the individual average strain curve. The interventricular septum was included in the LS measurements for both the left and right ventricles. The interatrial septum was likewise included in the LS measurements for both the left and right atria. To assess LV volumes and ejection fraction, the region of interest was manually traced in the three apical views at the end-diastolic frame using a different software (EchoInsight for Cardio Oncology; Epsilon Imaging). The software automatically performed speckletracking analysis on a frame-by-frame basis and generated timedomain regional LS curves. After completion of speckle-tracking in all three apical views, the software provided LV global LS. The software also provided LV end-diastolic and end-systolic volumes and LV ejection fraction using the biplane Simpson formula. Although both LV LS and LV global LS were obtained, we used only LV LS in the analysis. Tricuspid annular plane systolic excursion and RV fractional area change were obtained by a RV-focused view (EchoInsight for RV; Epsilon Imaging). Because the negative values of LV LS and RV LS can cause confusion, the absolute values of LV LS and RV LS are instead reported in the text, figures, and tables. Thus, higher LV and RV strain values represent improved LV and RV function LV mass was calculated from measurements of LV wall thickness

and chamber dimension, and LA volumes were calculated using the biplane area-length method.¹⁷ Both LV and LA volumes and LV mass were subsequently indexed to body surface area. The early filling (E-wave) and peak late diastolic (A-wave) velocities were obtained from the transmitral flow. The peak systolic (s'), early diastolic (e'), and late diastolic (a') mitral annular velocities were recorded at the septal corner of the mitral annulus. The ratio of early mitral diastolic inflow velocity to early diastolic mitral annular velocity (E/e') was also calculated. Diastolic dysfunction was categorized into four groups according to previous reports (normal, impaired relaxation, pseudonormal, or restrictive).¹⁸

Observer Variability

The reproducibility of strain measurements (LV, RV, LA, and RA LS) was assessed in 15 randomly selected patients. Intra- and interobserver variabilities were evaluated after the same observer and another reader repeated the analysis 3 months later and are reported as percentage variability, defined as the absolute difference in percentage of the mean of repeated measurements and intraclass correlation coefficient. Download English Version:

https://daneshyari.com/en/article/5612215

Download Persian Version:

https://daneshyari.com/article/5612215

Daneshyari.com